Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2025
0mins
Source: MarketWatch
Pfizer's Investment in Cancer Treatment: Pfizer Inc. is investing billions to develop a new cancer treatment and has entered into a licensing agreement with Chinese company 3SBio Inc.
Targeted Antibody Development: The collaboration focuses on creating an antibody, SSGJ-707, that targets PD-1 and VEGF to enhance the immune system's ability to combat cancer cells.
Analyst Views on BNTX
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 118.470
Low
116.00
Averages
141.93
High
181.00
Current: 118.470
Low
116.00
Averages
141.93
High
181.00
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
